US stock · Healthcare sector · Drug Manufacturers—General
Company Logo

Eli Lilly and Company

LLYNYSE

446.04

USD
+0.38
(+0.09%)
Market Closed
70.85P/E
36Forward P/E
2.90P/E to S&P500
423.414BMarket CAP
0.91%Div Yield
Upcoming Earnings
8 Aug
Shares Short
5/31/23
6M
Short % of Float
0.76%
Short % of Shares Outs.
0.63%
% Held by Insiders
0.15%
% Held by Institutions
84.00%
Beta
0.37
PEG Ratio
2.09
52w. high/low
454.95/283.11
Avg. Daily Volume
3.24M
Return %
Stock
S&P 500
1 year
49.05
9.18
3 years
195.16
34.24
5 years
419.07
55.11
Scale: |
High
Low
57.52
28.62
40.78
27.21
38.08
32.02
41.92
33.46
53.99
38.30
58.41
47.53
75.10
50.52
92.85
68.31
85.40
64.18
89.09
73.54
119.84
73.69
137.00
101.36
173.90
117.06
283.90
161.78
375.25
231.87
454.95
309.20
Currency: USD
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
Revenue per share
17.10
18.62
19.88
20.87
21.80
19.72
20.70
17.66
18.06
19.28
21.74
23.89
23.31
25.65
31.22
31.65
30.31
Earnings per share
2.71
(1.89)
3.94
4.58
3.90
3.57
4.19
2.15
2.18
2.49
(0.19)
3.14
8.69
6.47
6.15
6.93
6.20
FCF per share
3.74
5.80
3.17
5.13
4.97
3.72
4.16
2.52
1.04
3.41
3.28
2.44
3.64
4.67
5.94
5.80
4.14
Dividends per share
1.70
1.88
1.96
1.96
1.96
1.91
1.90
1.89
1.92
1.96
2.08
2.25
2.52
2.81
3.40
3.92
4.01
CAPEX per share
0.99
0.87
0.78
1.07
1.52
0.91
0.98
1.41
1.47
0.99
2.06
2.94
1.41
2.12
2.07
2.06
2.77
Book Value per sh.
12.54
6.15
8.67
11.23
12.16
12.88
15.79
13.84
13.18
12.72
11.02
9.56
2.72
5.90
9.90
11.81
11.07
Comm.Shares outs.
1,090
1,094
1,098
1,106
1,114
1,146
1,117
1,111
1,105
1,101
1,052
1,028
958
957
907
902
914
Avg. annual P/E ratio
20.4
(24.1)
8.7
7.7
9.4
12.2
12.6
28.7
36.3
30.7
(423.4)
29.7
13.4
22.7
36.4
44.4
70.8
P/E to S&P500
1.2
(1.1)
0.1
0.4
0.6
0.8
0.7
1.6
1.8
1.4
(17.9)
1.2
0.6
0.6
1.2
2.1
2.9
Avg. annual div. yield
3.1%
4.1%
5.7%
5.6%
5.3%
4.4%
3.6%
3.1%
2.4%
2.6%
2.5%
2.4%
2.2%
1.9%
1.5%
1.3%
1.1%
Revenue (m)
18,634
20,378
21,836
23,076
24,287
22,603
23,113
19,616
19,959
21,222
22,871
24,556
22,320
24,540
28,318
28,541
27,691
Operating margin
25.8%
27.1%
29.2%
29.3%
22.8%
20.9%
23.2%
13.6%
13.5%
16.3%
9.4%
25.2%
22.3%
24.7%
22.4%
29.0%
25.7%
Depreciation (m)
1,048
1,123
1,298
1,328
1,374
1,462
1,446
1,379
1,428
1,497
1,567
1,609
1,233
1,324
1,548
1,523
1,478
Net profit (m)
2,953
(2,072)
4,329
5,070
4,348
4,089
4,685
2,391
2,408
2,738
(204)
3,232
8,318
6,194
5,582
6,245
5,687
Income tax rate
23.8%
(58.5)%
19.2%
22.3%
18.7%
24.4%
20.5%
20.3%
13.7%
18.9%
109.3%
14.9%
11.9%
14.3%
9.3%
8.3%
9.9%
Net profit margin
15.8%
(10.2)%
19.8%
22.0%
17.9%
18.1%
20.3%
12.2%
12.1%
12.9%
(0.9)%
13.2%
37.3%
25.2%
19.7%
21.9%
20.4%
Working capital (m)
6,989
(656)
5,918
7,739
5,317
4,649
4,188
972
4,344
4,115
4,666
8,662
1,934
4,981
3,400
896
4,801
Long-term debt (m)
4,594
4,616
6,635
6,771
5,465
5,519
4,200
5,368
7,972
8,368
9,941
11,640
13,818
16,587
15,346
14,738
18,881
Equity (m)
13,664
6,735
9,524
12,420
13,542
14,765
17,631
15,373
14,571
14,008
11,592
9,829
2,607
5,642
8,979
10,650
11,190
ROIC
13.7%
(12.9)%
21.7%
21.8%
18.2%
16.2%
18.3%
9.7%
9.3%
10.4%
(0.7)%
11.2%
30.0%
19.1%
17.5%
18.6%
17.2%
Return on capital
14.5%
(4.5)%
20.5%
21.6%
16.4%
16.2%
17.2%
8.5%
8.3%
9.2%
5.4%
9.5%
23.8%
16.3%
13.4%
13.2%
13.4%
Return on equity
21.6%
(30.8)%
45.5%
40.8%
32.1%
27.7%
26.6%
15.5%
16.5%
19.5%
(1.8)%
32.9%
319.1%
109.8%
62.2%
58.6%
50.8%
Plowback ratio
37.2%
199.3%
50.3%
57.3%
49.9%
46.5%
54.7%
12.1%
11.7%
21.2%
1,174.0%
28.5%
71.0%
56.6%
44.7%
43.4%
35.5%
Div.&Repurch./FCF
44.9%
- -
61.8%
38.2%
39.3%
68.3%
82.3%
103.6%
250.9%
73.4%
- -
191.6%
195.5%
71.3%
80.5%
96.3%
116.7%
Capital Structure
27 Apr · 2023 | Q1
All numbers in millions
Total liabilities
$ 41,868
Total assets
$ 53,163
Long-term debt
$ 18,881
Cash and equiv.
$ 3,546
Goodwill
$ 4,073
Retained earnings
$ 10,639
Common stock
903
Enterprise Value
$ 438,748
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
3,681
3,909
2,212
Receivables
6,929
8,127
8,559
Inventory
3,980
3,886
4,310
Other
2,872
2,692
1,364
Current assets
17,462
18,452
18,035
Acc. Payable
1,607
1,671
1,931
Debt due
9
1,538
1,501
Other
10,866
11,844
13,707
Current liabilities
12,482
15,053
17,138
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
0.79%
4.26%
2.79%
Cash flow
(2.92)%
21.23%
19.83%
Earnings
11.88%
33.46%
(187.97)%
Dividends
14.55%
11.29%
6.00%
Book value
18.61%
30.17%
7.37%
Insider Trading
Type
Shares
Date
Rau Diogo
Exempt
6,300
06/01/23
Rau Diogo
InKind
2,848
06/01/23
Rau Diogo
Exempt
6,300
06/01/23
Jonsson Patrik
Sale
6,000
06/01/23
Lilly Endowment Inc
Sale
163,571
05/19/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2021
6,806
6,740
6,773
8,000
28,318
2022
7,810
6,488
6,942
7,302
28,541
2023
6,960
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
1.49
1.53
1.22
1.90
6.15
2022
2.11
1.06
1.61
2.15
6.93
2023
1.49
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
0.85
0.85
0.85
0.85
3.40
2022
0.98
0.98
0.98
0.98
3.92
2023
1.13
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Drug Manufacturers—General
CEO:
Mr. David A. Ricks
Full-time employees:
39,000
City:
Indianapolis
Address:
Lilly Corporate Center
IPO:
Jul 9, 1970
Website:
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Recent News
· 3 May, 2023 · The Wall Street Journal
· 3 May, 2023 · The Wall Street Journal
· 8 Mar, 2023 · The Wall Street Journal
· 1 Mar, 2023 · The Wall Street Journal
· 2 Feb, 2023 · The Wall Street Journal
· 4 Dec, 2022 · The Wall Street Journal
· 30 Nov, 2022 · The Wall Street Journal
· 6 Aug, 2022 · The Wall Street Journal
· 5 Aug, 2022 · The Wall Street Journal
· 29 Jun, 2022 · The Wall Street Journal
· 21 Jun, 2022 · The Wall Street Journal
· 24 May, 2022 · The Wall Street Journal
· 24 Mar, 2022 · The Wall Street Journal
· 26 Oct, 2021 · The Wall Street Journal
· 30 Jul, 2021 · The Wall Street Journal
· 24 Jun, 2021 · The Wall Street Journal